logo
  

Novartis Announces Lucentis Approval In Fourth Japanese Indication - Quick Facts

Swiss pharma giant Novartis AG (NVS) announced that Lucentis (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: to treat patients with diabetic macular edema or DME, a main cause of vision loss among patients with diabetes. Laser therapy, the current standard of care in Japan, has provided stabilization of vision in many patients, but generally does not improve vision. Lucentis is the first licensed therapy to significantly improve vision in Asian patients with visual impairment due to DME.

Tim Wright, Global Head of Development, Novartis Pharmaceuticals, said: "Lucentis has previously been shown to be an effective treatment, improving vision loss and vision-related quality of life for patients with DME." He continued, "Now Japanese patients living with DME have access to Lucentis, a drug with an unsurpassed efficacy and safety profile across multiple indications."

The Lucentis approval as based on the REVEAL trial results, the first randomized study designed specifically to evaluate the efficacy and safety of Lucentis in Asian patients with visual impairment due to DME. Efficacy and safety results from the REVEAL study were similar to other DME trials primarily conducted in Caucasians.

At 12 months, REVEAL confirmed the superior efficacy of Lucentis with rapid and sustained visual acuity gains compared with laser therapy. The safety results demonstrated that Lucentis was well tolerated in patients with DME both as monotherapy or when administered with laser.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Natreve, a premium wellness company, is recalling certain Vegan Protein Powder due to undeclared milk, a known allergen, the U.S. Food and Drug Administration said. The recall involves specific batches of its Vegan Protein Powder French Vanilla Wafer Sundae flavor. The impacted products are stored in 13 oz (10 servings) and 1.47lb (18 servings) white tubs. The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement.
Follow RTT